Strados Labs Revenue and Competitors

Strados Labs is a medical technology company that specializes in advancing respiratory health management using clinical-grade biosensors and intelligent software. Reports have it that readmission rates after exacerbation of chronic lung diseases, including chronic obstructive lung disease (COPD) and asthma still exceed 10% and in some settings may exceed 20% with impact on morbidity, mortality and health costs. In the US alone, these costs annually exceed $100B in direct + indirect costs for asthma and COPD. Hence, our top priority is to assist medical professionals in the monitoring and management of pulmonary conditions through innovative medical devices that reduce the probability of loss of control of airway disease. We believe that by continuously capturing asymptomatic signs of individuals and population of patients, treatment and medication will become more effective. Our first product is a clinical grade biosensor that provides information about the pulmonary performance of patients' in real-time. Through its easy to wear flexible sensors, it collects data passively and continuously. The insights it provides help extend patient monitoring through the entire health care continuum. As a spirited, fast-growing medical technology company, our customers and partners can benefit immensely from specialized market expertise with high level of professionalism. Our medical technology company is at its early stage, our patent-pending technology is currently being evaluated in clinical studies and pilots across the United States. This product is not yet available for sale in the USA or internationally. It has not been approved by FDA or any other regulatory agency.